Co-Existence of Congenital Adrenal Hyperplasia and Familial Hypokalemic Periodic Paralysis due to \textit{CYP21A2} and \textit{SCN4A} Pathogenic Variants

Running Head: Case with CYP21A2 and SCN4A Pathogenic Variants

Tuğba Çetin1, İhsan Turan2
1Sanliurfa Eğitim ve Araştırma Hastanesi Ringgold standard institution - Pediatric Endocrinology, Sanliurfa, Turkey
2Cukurova University Faculty of Medicine Ringgold standard institution - Pediatric Endocrinology, Adana, Turkey

What is already known on this topic?
Pathogenic variant in the gene encoding \textit{CYP21A2} is the most common cause of congenital adrenal hyperplasia. Familial hypokalemic periodic paralysis is a rare disorder in which affected individuals may experience paralytic episodes associated with hypokalemia caused by pathogenic variants in \textit{SCN4A} and \textit{CACNA1S}. It is necessary to remember the importance of watching the medical steps in every clinical assessment. It is important to question the patient's and family members' medical history and to identify family members at risk by segregation analyses.

What this study adds?
This is the first case report of 21-hydroxylase enzyme deficiency and familial hypokalemic periodic paralysis in the literature. Elevated ACTH and androgens may trigger a hypokalemia attack in familial hypokalemic periodic paralysis. It is necessary to reconsider routine fludrocortisone treatment in children with 21-hydroxylase enzyme deficiency based on upcoming fields of knowledge areas.

Abstract
Steroid 21-hydroxylase deficiency is the most common cause of congenital adrenal hyperplasia biallelic variants in \textit{CYP21A2}. The classical 21-hydroxylase deficiency is characterised by virilisation of the external genitalia in females and hypocortisolism. Hyponatremia and hyperkalemia are among the common biochemical findings. Familial hypokalemic periodic paralysis (FHPP) is a rare disorder in which affected individuals may experience paralytic episodes associated with hypokalemia, caused by pathogenic variants in \textit{SCN4A} and \textit{CACNA1S}. A 14-year-old female, who had been diagnosed with classical 21-hydroxylase deficiency and treated with hydrocortisone and fludrocortisone since early infancy, presented with acute onset weakness. The laboratory results revealed a remarkably low serum potassium level. The family history revealed that both her father and uncle had the same hypokalemia symptoms, which suggested an FHPP diagnosis. We found two previously reported homozygous variants in \textit{CYP21A2} (p.Ile173Asn) and \textit{SCN4A} (p.Arg672His) in the patient. Therefore, diagnoses of simple virilising 21-hydroxylase deficiency and FHPP were genetically confirmed. Here, FHPP and chronic overtreatment with fludrocortisone may explain the presentation of our patient with severe hypokalemia. The family's medical history, which is always a valuable clue, should be investigated in detail since we can encounter rare situations in geographies where consanguineous marriages are common and the genetic pool is diverse. In patients with congenital adrenal hyperplasia, care should be taken to avoid overtreatment with fludrocortisone. Androgens may have triggered the hypokalemia attack in familial hypokalemic periodic paralysis, as supported in a previous study.

Keywords: CYP21A2, SCN4A, Familial Hypokalemic periodic paralysis, Congenital Adrenal Hyperplasia
epidemic potassium transfer into the cells and causes weakness due to calcium channel defect is not precisely understood. The initial symptoms occur during the first or second decades of life, and these attacks vary in frequency and duration (2). To our knowledge, this is the first case report of familial hypokalemic periodic paralysis co-existence with 21-hydroxylase enzyme deficiency, which causes a reversed pathology in blood potassium levels.

**Case Report**

A 14-year-old female presented with acute onset weakness in both upper and lower extremities, which had progressed over 1 day. The medical history revealed that she was diagnosed with 21OHD as a new-born and was given oral hydrocortisone and fludrocortisone treatment. The patient was born at term in another primary care centre. Unfortunately, we could not retrieve detailed data on the laboratory parameters before her referral to our clinic. She presented with clitoromegaly, electrolyte imbalance, elevated ACTH and elevated 17-OH progesterone; to the best of our knowledge ACTH stimulation tests were not performed. She had undergone clitoroplasty in infancy. Six months before a hypokalemic attack, while she was under hydrocortisone (17 mg/m²/day-irregularly) and fludrocortisone (0.1 mg/day) treatment, her total testosterone (1.03 ng/mL), 17-OH progesterone (162 ng/mL) and ACTH (190 pg/mL) levels were elevated, reflecting poor control. The patient, who was under poor metabolic control, developed central precocious puberty with advanced bone age and received GnRH analogue treatment until 11 years of age. There was a consanguineous marriage between her parents.

She presented with severe generalised weakness in both arms and legs in our pediatric emergency clinic, which was our first evaluation of her. There was no history of fever, acute gastroenteritis, substance abuse or carbohydrate-rich meal or exercise before the paralysis episodes. She had no history of recent upper respiratory tract infection or vomiting, and she did not experience any neurological symptoms. She had not had similar episodes in the past, but her father and uncle had a history of paralytic episodes accompanied by hypokalemia without a genetic diagnosis. The muscle strength in both arms and legs was at grade two, and reflexes were absent. Blood pressure was 100/70 mm Hg. The rest of the physical examination was unremarkable. Complete blood count, blood gas, blood urea nitrogen, creatinine, creatine phosphokinase, serum electrolytes (calcium, phosphate, magnesium) were in the normal ranges; serum potassium and sodium levels were 1.9 mEq/L and 146 mmol/L, respectively. Hyperthyroidism was excluded.

She was admitted to the hospital, fludrocortisone treatment was terminated, intravenous potassium replacement was initiated. When the lower limit of the normal serum potassium level was achieved, intravenous potassium treatment was stopped, and oral potassium (citrate and bicarbonate) administration was initiated. Oral potassium was preferred to intravenous treatment to reduce the risk of rebound hyperkalemia and discontinuation of the normal serum potassium level. Cardiac activity and serum electrolyte levels were monitored during and after the treatment. Potassium levels were closely checked for potential rebound hyperkalemia for 24 hours. In her first endocrinology evaluation 15 days after the hypokalemic attack without fludrocortisone treatment, her laboratory examinations showed normal plasma aldosterone concentration of 30 ng/dL (4-58 ng/dL) and normal plasma renin activity (PRA) of 2.38 ng/mL/hr (2.3–37.0 ng/mL/hr) with normal blood pressure. The levels of biochemical parameters of the patient are shown in Table 1.

The patient's clinic and laboratory findings and family history were consistent with FHPP. Although the patient's father had the same diagnosis, FHPP, genetic analysis had not been performed before. Blood samples for genetic analyses were obtained after informed consent was received from the patient and her parents. Sanger sequencing in the proband revealed a homozygous p.Ile173Asn (c.518T > A) pathogenic variant in **CYP21A2** (NM_000500.9). The patient's mother and father were heterozygous for this variant. No pathogenic variant was detected in **SCN4A**. The sequencing of **SCN4A** (NM_000334.4) in the proband identified the previously reported heterozygous p.Arg672His (c.2015G > A) variant. Her affected father and uncle were heterozygous for this variant. Two variants were considered to be the 'pathogenic' variants based on the 2015 ACMG/AMP guideline. Pedigree and segregation analyses are shown in Figure 1.

**Discussion**

Here, we present the first patient with co-existence of congenital adrenal hyperplasia and hypokalemic periodic paralysis. This is a rare case that presented with hypokalemia and a tendency of hypokalemia due to 21OHD. In CYP21A2, T-to-A change at nucleotide 518 was predicted to be a substitution of the isoleucine at residue 173 for asparagine, p.Ile173Asn. This pathogenic variant has been widely reported in 21OHD, and functional analysis has been performed (3,4). The p.Arg672His variant was located at a hotspot region in SCN4A. The missense variant was not found in gnomAD. Alternative variants Arg672Ser, Gly, Gly and Ser have been reported previously (5). Jurkat-Rott et al. reported a family with hypokalemic periodic paralysis type 2, in whom the family member had p.Arg672His in SCN4A (6). Lastly, this variant was considered as the 'pathogenic' variant based on the 2015 ACMG/AMP guideline. These findings led us to conclude that this variant is the disease-causing variant.

Silent carrier activity is 1–5% in patients with p.Ile173Asn in CYP21A2, most patients do not need fludrocortisone treatment. The presence of homozygous p.Ile173Asn genotype, classified in group c, predicts simple virilising 21OHD; however, these patients tend to have hyperkalemia (3,4). Fludrocortisone treatment is initiated before the definite diagnosis, as suggested in congenital adrenal hyperplasia guidelines because of its life-threatening nature, causing 25% of patients to receive unnecessary fludrocortisone treatment (1). It is necessary to measure PRA and aldosterone levels, blood pressure and serum electrolytes of each patient with 21OHD to avoid overtreatment or mistreatment. We observed that this management was insufficient in the patient's history.

Additionally, genetic analysis is guiding in these patients (3,7). Before deciding on such treatment, it is vital to review all possibilities, take a careful medical history and family history and perform a physical examination. Here, CYP21A2 genetic analysis is also highly useful in deciding upon fludrocortisone treatment (3). It was unusual to detect hypokalemia with a sign of hyperaldosteronism in a case where we expected a possible lack of aldosterone production. However, the patient's family history
was suspicious for hypokalemic periodic paralysis. We determined that genetic analysis had not been performed for any family members before, although molecular genetic confirmation of the possible diagnosis is extremely helpful in such complex situations. In this patient, genetic testing confirmed an autosomal dominant SCN4A-related disorder and a simple virilising form of 21OHD. Fludrocortisone treatment was discontinued gradually, with a molecular genetic prediction as it could exacerbate possible episodes of hypokalemia. As research in upcoming fields, such as molecular genetics and metabolomics, increases, more evidence-based approaches may be created rather than empirical treatments. This provides a better medical approach to orphan cases. In our patient, when the serum potassium level was 1.9 serum mEq/L, the serum sodium level was 146 mmol/L, at the upper end of the range. Additionally, 15 days after the hypokalemic attack, PRA seemed to be suppressed at the lower end of the range without fludrocortisone treatment. This finding led us to infer that mistreatment of fludrocortisone may have aggravated hypokalemia.

When patients are evaluated after or between attacks, FHPP diagnosis may be challenging. Molecular genetic testing is recommended when the diagnosis of FHPP is suspected (2). Other diagnostic options include provocative testing and electromyography. Provocative testing with oral glucose, insulin, exercise and ACTH can induce FHPP (8). The father and uncle of the case, carrying the same variant in SCNN4, had experienced their first hypokalemia attack in their 20s. Although there is an opinion that penetrance is lower in women, our case had her first attack at the age of 14. Hypokalemia that occurs earlier than we expected could be due to two reasons: first, based on the ACTH provocation test, the elevated ACTH, due to poor metabolic disease control, may trigger the attack; second, elevated androgens with 21OHD may trigger an attack in FHPP, as shown in the study of Qing Ke et al. (9).

Our patient had undergone clitoroplasty in infancy, without any complications. The association between malignant hyperthermia and hypokalemia is uncertain, but has been described previously (10). If surgery with general anaesthesia is required, patients should be monitored for signs of malignant hyperthermia. However, in a future surgical operation, the surgeon, anaesthesiologist and endocrinologist should evaluate possible risks and take the necessary precautions. Simultaneously, the patient was warned about drugs and general anaesthesia that could trigger an attack. In this patient's clinical management, with two co-existing conditions, we advised her to have a low-carbohydrate diet and to refrain from strenuous exercise to prevent hypokalemic attacks. However, potassium-sparing treatment is not preferred for the risk of hyperkalemia. It can, paradoxically, worsen hypokalemia. As soon as symptoms begin, we recommend that hypokalemia must be confirmed with blood tests before potassium therapy. The patient was educated about the regular use of glucocorticoid therapy to avoid poor metabolic control with CAH. In medical evaluation, it is essential to question the patient's and family members' health history. The pedigree is much more critical. Many patients are not diagnosed, and their diseases are not defined due to insufficient examination time and clinical attention, as well as a lack of medical information, especially in orphan patients. This is the group of patients who suffer most from the difficulties in getting appropriate support. According to our clinical experience from these cases, identifying individuals at risk with segregation analysis after taking a complete family history will keep the case safer in terms of future risky situations.

**Conclusion**

In our case, a disease predisposing to hypokalemia, with 21OHD, was suspected at the first evaluation, and molecular genetic tests supported the diagnosis. Periodic paralysis is a rare disease, and the possibility of concomitant 21OHD is extremely low. More rare situations can be encountered in genetics where consanguineous marriage is common and the genetic pool is diverse. Due to the heavy patient load, the insufficient number of doctors and the presence of widespread routine algorithms, such rare cases can be missed. In this case, our experiences led us once again, to the importance of knowing one's family medical history, which allows the clinician to reduce the possible risks. Family members at risk should be identified by segregation analysis in inherited genetic diseases and disorders. Androgens may have triggered the hypokalemic attack in familial hypokalemic periodic paralysis, as supported in a previous study, and overtreatment of fludrocortisone may have aggravated hypokalemia.

**Ethics**

**Informed Consent:** The subject and her parents have given their written informed consent to publish their case in accordance with the Declaration of Helsinki.

**Authorship Contributions:** Medical practices, concept, design, analysis or interpretation, writing, data collection or processing and literature search: Tugba Cetin, Ilhsan Turan.

**Financial Disclosure:** The authors declared that this study received no financial support.

**Conflict of Interest:** No author has any potential conflict of interest.

**References**


Table 1. The levels of biochemical parameters of the patient

<table>
<thead>
<tr>
<th>Time according to hypokalemic attack</th>
<th>Na mmol/L (136-146)</th>
<th>K mEq/L (3.5-5.5)</th>
<th>t-testosterone ng/dL (2.3-13.9)</th>
<th>17-OH progesterone ng/mL (0.4-12)</th>
<th>ACTH pg/mL (10-60)</th>
<th>Aldosterone ng/dL (4-58)</th>
<th>PRA ng/mL/hr (2.3-37.0)</th>
<th>Blood pressure mm/Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Six months before</td>
<td>141</td>
<td>4.2</td>
<td>133</td>
<td>53</td>
<td>67</td>
<td>na</td>
<td>na</td>
<td>normotensive*</td>
</tr>
<tr>
<td>Three months before</td>
<td>142</td>
<td>4.5</td>
<td>103</td>
<td>162</td>
<td>190</td>
<td>na</td>
<td>na</td>
<td>normotensive*</td>
</tr>
<tr>
<td>Days of attack</td>
<td>146</td>
<td>1.9</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>100/70</td>
</tr>
<tr>
<td>15 days’ after</td>
<td>143</td>
<td>4.6</td>
<td>na</td>
<td>na</td>
<td>36.8</td>
<td>2.38</td>
<td>90/60</td>
<td></td>
</tr>
</tbody>
</table>

t-testosterone: total testosterone, PRA, Plasma Renin Activity, na: not available,*: blood pressure value unspecified, reported normotensive in data, Numbers in parentheses refer to normal values.

Figure 1.